Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.

abstract：:Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poo...

journal_title：Expert review of anticancer therapy

authors： Wardak Z,Choe KS

更新日期：2013-11-01 00:00:00

abstract：:Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer. Optimizing the management of frequent crizotinib-related adverse events is crucial to ensure its continuous administration and reprodu...

journal_title：Expert review of anticancer therapy

authors： Girard N,Audigier-Valette C,Cortot AB,Mennecier B,Debieuvre D,Planchard D,Zalcman G,Moro-Sibilot D,Cadranel J,Barlési F

更新日期：2015-02-01 00:00:00

abstract：:Stereotactic body radiation therapy (SBRT) involves delivery of image-guided, ablative radiation doses to planning treatment volume(s) using sophisticated dosimetric planning and target localization. Early on, clinical investigators pursued SBRT for the treatment of early stage non-small-cell lung cancer, lung and liv...

journal_title：Expert review of anticancer therapy

authors： Mayr NA,Huang Z,Sohn JW,Lo SS,Teh BS,Lu JJ,Grecula JC,Kunos C

更新日期：2011-07-01 00:00:00

abstract：:The development of consensus classifications for renal epithelial neoplasia in 1996 and 1997 led to the recognition of renal adenoma, renal oncocytoma and metanephric adenoma/adenofibroma as benign tumors and conventional (clear cell) renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and collecting duct carci...

journal_title：Expert review of anticancer therapy

authors： Delahunt B,Velickovic M,Grebe SK

更新日期：2001-12-01 00:00:00

abstract：:This article reviews the current status of robotic-assisted radical prostatectomy (RARP) with outcome analysis. The published English literature (PubMed) database was searched extensively for major publications and large series on RARP. The search was carried out over the preceding 3-year period. Selected series were ...

journal_title：Expert review of anticancer therapy

authors： Singh I,Hemal AK

更新日期：2010-05-01 00:00:00

abstract：INTRODUCTION:Intrahepatic cholangiocarcinoma (ICC) is a highly malignant neoplasm. The incidence of ICC has been increasing world-wide over the past several decades. Areas covered: The pathogenesis of ICC is a complex process involving the alteration of specific genes and epigenetic changes. This review summarizes the ...

journal_title：Expert review of anticancer therapy

authors： Huang SB,Zheng CX

更新日期：2017-01-01 00:00:00

abstract：:Nonmelanoma skin cancer is the most prevalent malignant disease among light-skinned individuals in the USA, accounting for approximately 1 million new cases annually. Solar ultraviolet radiation is known to be the major cause of skin cancer. The idea that diet, particularly dietary fat, may play a role in modulating c...

journal_title：Expert review of anticancer therapy

authors： Black HS

更新日期：2005-10-01 00:00:00

abstract：:Since its introduction almost 40 years ago, intravesical BCG for non-muscle invasive bladder cancer remains one of the most successful cancer immunotherapies. However, up to 40% of patients will progress after BCG therapy and develop invasive bladder cancer. Despite its extensive clinical use, we are only beginning to...

journal_title：Expert review of anticancer therapy

authors： Wu Y,Enting D,Rudman S,Chowdhury S

更新日期：2015-05-01 00:00:00

abstract：:Although available targeted therapies provide some clinical efficacy, a need remains for antiangiogenic therapies with alternative mechanisms in order to provide better outcomes and the ability to circumvent resistance. Inhibition of multiple VEGF targets may produce enhanced efficacy and more durable responses throug...

journal_title：Expert review of anticancer therapy

authors： Gordon MS

更新日期：2011-03-01 00:00:00

abstract：:There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

journal_title：Expert review of anticancer therapy

authors： Bazargan A,Tam CS,Keating MJ

更新日期：2012-03-01 00:00:00

abstract：:Introduction: Despite dramatic improvements in survival achieved with currently available anti-HER2 agents, HER2-positive metastatic breast cancer remains an almost invariably deadly disease, with primary or acquired resistance to HER2-directed agents developing during treatment. Many efforts are focused on identifyin...

journal_title：Expert review of anticancer therapy

authors： Viale G,Morganti S,Ferraro E,Zagami P,Marra A,Curigliano G

更新日期：2019-09-01 00:00:00

abstract：:Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleo...

journal_title：Expert review of anticancer therapy

authors： Robak T

更新日期：2008-07-01 00:00:00

abstract：:As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for ...

journal_title：Expert review of anticancer therapy

authors： Batus M,Fidler MJ,Bonomi PD

更新日期：2010-10-01 00:00:00

abstract：:Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

journal_title：Expert review of anticancer therapy

authors： Kortmann RD

更新日期：2014-01-01 00:00:00

abstract：:Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamo...

journal_title：Expert review of anticancer therapy

authors： Bria E,Carlini P,Cuppone F,Vaccaro V,Milella M,Cognetti F

更新日期：2010-08-01 00:00:00

abstract：:Knowledge of the prognostic role of biomarkers in colorectal cancer is limited and the routine determination for clinical practice is not warranted. However, for some of these markers, data are promising enough for further evaluation. This review addresses a comprehensive analysis of prognostic biomarkers in colorecta...

journal_title：Expert review of anticancer therapy

authors： Graziano F,Catalano V,Baldelli AM,Cascinu S

更新日期：2001-08-01 00:00:00

abstract：:Positron emission tomography (PET) using [(18)F]-2-deoxy-2-fluoro-d-glucose (FDG) has emerged as a valuable diagnostic modality in patients with non-small cell lung cancer (NSCLC). Data in the literature show that the addition of FDG-PET definitely alters clinical management in patients with potentially resectable NSC...

journal_title：Expert review of anticancer therapy

authors： Oyen WJ,Bussink J,Verhagen AF,Corstens FH,Bootsma GP

更新日期：2004-08-01 00:00:00

abstract：:Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

journal_title：Expert review of anticancer therapy

authors： Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

更新日期：2010-07-01 00:00:00

abstract：:Metastasis contributes to over 90% of cancer-related deaths. Many types of cancer metastasize via the bloodstream, where circulating tumor cells (CTCs) originating from the primary tumor can undergo selectin-mediated adhesion with the blood vessel wall and subsequently transmigrate to anatomically distant organs. In a...

journal_title：Expert review of anticancer therapy

authors： Mitchell MJ,King MR

更新日期：2014-06-01 00:00:00

abstract：INTRODUCTION:Adrenocortical carcinoma (ACC) is a rare tumor characterized by poor prognosis in most cases. Moreover, in most cases ACC produces an excess of adrenal steroid hormones with relevant clinical consequences. Areas covered: After an extensive literature search, this narrative review addresses diagnostic manag...

journal_title：Expert review of anticancer therapy

authors： Puglisi S,Perotti P,Cosentini D,Roca E,Basile V,Berruti A,Terzolo M

更新日期：2018-11-01 00:00:00

abstract：:Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

journal_title：Expert review of anticancer therapy

authors： Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

更新日期：2016-01-01 00:00:00

abstract：:Introduction: Management of clinically negative neck (cN0) in patients with parotid gland cancer is controversial. Treatment options can include observation, elective neck dissection or elective radiotherapy. Areas covered: We addressed the treatment options for cN0 patients with parotid gland cancer. A literature rev...

journal_title：Expert review of anticancer therapy

authors： Vartanian JG,Gonçalves Filho J,Kowalski LP,Shah JP,Suárez C,Rinaldo A,De Bree R,Rodrigo JP,Hamoir M,Takes RP,Mäkitie AA,Zbären P,Andreasen S,Poorten VV,Sanabria A,Hellquist H,Robbins KT,Bödeker CC,Silver C,Ferlito A

更新日期：2019-10-01 00:00:00

abstract：:A number of important studies were presented at the CNS tumors section of the 2010 American Society of Oncology (ASCO) Annual Meeting. There was particular interest in a Phase II study showing that the mTOR inhibitor everolimus had significant activity in tuberous patients with subependymal giant cell astrocytomas. Tw...

journal_title：Expert review of anticancer therapy

authors： Wen PY

更新日期：2010-09-01 00:00:00

abstract：:Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis. It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths. Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical man...

journal_title：Expert review of anticancer therapy

authors： Haleblian GE,Wilson C,Haddad D,Albala DM

更新日期：2007-09-01 00:00:00

abstract：:Background: Patients with metastatic renal cell carcinoma (mRCC) are commonly treated with tyrosine kinase inhibitors (TKIs). An adverse effect frequently suffered by patients is lethargy, which often leads to dose reduction or drug cessation. We aimed to assess whether hypogonadism is related to treatment with TKIs. ...

journal_title：Expert review of anticancer therapy

authors： Afshar M,Patel HRH,Jain A,Kumar A,Patel P,James ND,Porfiri E

更新日期：2019-06-01 00:00:00

abstract：:Background: This evaluation emphasizes the main points of the original article 'Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies' by Sprenger et al. and provides further justification for the use of an alternative approach in the design...

journal_title：Expert review of anticancer therapy

authors： Roussos Torres ET,Epstein AL

更新日期：2021-01-19 00:00:00

abstract：:Introduction: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour, and its outcome is strongly conditioned by the rapid onset of resistance to conventional chemotherapeutics. First-line treatment with a combination of platinum agents and topoisomerase inhibitors has been the standard of care for...

journal_title：Expert review of anticancer therapy

authors： Van Den Borg R,Leonetti A,Tiseo M,Giovannetti E,Peters GJ

更新日期：2019-06-01 00:00:00

abstract：:Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O,Alorabi M

更新日期：2015-01-01 00:00:00

abstract：:Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

journal_title：Expert review of anticancer therapy

authors： Sigal DS,Saven A

更新日期：2008-04-01 00:00:00

abstract：:Bladder cancer is rare in patients below the age of 50 years, and most patients are in their 60s and 70s. Radical cystectomy is the preferred approach for patients with localized disease in most European countries and the USA, and evidence is growing in favor of neoadjuvant, platinum-based chemotherapy for patients at...

journal_title：Expert review of anticancer therapy

authors： Basso U,Bassi P,Sava T,Monfardini S

更新日期：2004-12-01 00:00:00